Novo Nordisk to present updates on trial drug and Wegovy supply issue
The company is racing to increase output of the weight-loss drug Wegovy amid shortages
07 March 2024 - 11:09
byJacob Gronholt-Pedersen and Maggie Fick
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
A scientific model of the molecule semaglutide, which is the active ingredient in Novo Nordisk’s diabetes drug Ozempic and weight-loss drug Wegovy, sits in the office of CEO Mads Krogsgaard Thomsen in Hellerup, Denmark, on October 3, 2023. Picture: REUTERS/ALI WITHERS/FILE
Copenhagen — Novo Nordisk on March 7 said it would present early trial data for a highly anticipated pipeline obesity drug, and give an update on the supply of weight-loss drug Wegovy amid shortages.
In an era of unprecedented levels of obesity worldwide, Wegovy has transformed Danish drugmaker Novo, long known as a maker of insulin.
Novo is racing to increase output of the blockbuster drug Wegovy amid shortages, and in February scored a win when its parent company bought Catalent, a key manufacturing subcontractor of the product.
Novo said in a statement that it will “update on scaling of manufacturing capacity and plans to increase patient reach” as it hosts investors and analysts at its headquarters near Copenhagen for the first strategy update since Wegovy exploded in popularity.
Its market capitalisation stood at about $560bn going into the meeting compared with about $235bn two years ago when it last held an investor day.
Novo shares are up about 15% since the company reported full-year earnings on January 31, and have risen more than three-fold since June 2021 when it launched Wegovy in the US.
Nearly half of Novo’s current valuation is based on the company’s pipeline of new experimental drugs such as amycretin, the obesity drug it will give an update for on March 7, according to calculations by Berenberg analysts last week.
Analysts had hoped Novo would provide data at Thursday’s investor meeting after announcing on January 31 that the group had successfully completed an early stage trial of that experimental drug.
At that time, Novo’s head of research and development Martin Lange told an analyst call that the company believes amycretin is “properly differentiated to whatever else is out there”.
Analysts said Novo’s shares will likely rise if the company says that it expects amycretin to cause weight loss of greater than 25% — far higher than the 15% from Wegovy — in obese people without diabetes.
Following the success of obesity and type 2 diabetes drugs from the GLP-1 class, companies including Novo are working on promising therapies in clinical trials, such as amycretin and another drug, CagriSema, which target a hunger hormone called amylin.
CagriSema consists of two subsequent injections of a GLP-1 analogue called semaglutide, the same active ingredient in obesity drug Wegovy and diabetes drug Ozempic and an amylin analogue. The amycretin pill combines the two modes of action in one molecule.
The company is also working on an injectable version of amycretin.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Novo Nordisk to present updates on trial drug and Wegovy supply issue
The company is racing to increase output of the weight-loss drug Wegovy amid shortages
Copenhagen — Novo Nordisk on March 7 said it would present early trial data for a highly anticipated pipeline obesity drug, and give an update on the supply of weight-loss drug Wegovy amid shortages.
In an era of unprecedented levels of obesity worldwide, Wegovy has transformed Danish drugmaker Novo, long known as a maker of insulin.
Novo is racing to increase output of the blockbuster drug Wegovy amid shortages, and in February scored a win when its parent company bought Catalent, a key manufacturing subcontractor of the product.
Novo said in a statement that it will “update on scaling of manufacturing capacity and plans to increase patient reach” as it hosts investors and analysts at its headquarters near Copenhagen for the first strategy update since Wegovy exploded in popularity.
Its market capitalisation stood at about $560bn going into the meeting compared with about $235bn two years ago when it last held an investor day.
Novo shares are up about 15% since the company reported full-year earnings on January 31, and have risen more than three-fold since June 2021 when it launched Wegovy in the US.
Nearly half of Novo’s current valuation is based on the company’s pipeline of new experimental drugs such as amycretin, the obesity drug it will give an update for on March 7, according to calculations by Berenberg analysts last week.
Analysts had hoped Novo would provide data at Thursday’s investor meeting after announcing on January 31 that the group had successfully completed an early stage trial of that experimental drug.
At that time, Novo’s head of research and development Martin Lange told an analyst call that the company believes amycretin is “properly differentiated to whatever else is out there”.
Analysts said Novo’s shares will likely rise if the company says that it expects amycretin to cause weight loss of greater than 25% — far higher than the 15% from Wegovy — in obese people without diabetes.
Following the success of obesity and type 2 diabetes drugs from the GLP-1 class, companies including Novo are working on promising therapies in clinical trials, such as amycretin and another drug, CagriSema, which target a hunger hormone called amylin.
CagriSema consists of two subsequent injections of a GLP-1 analogue called semaglutide, the same active ingredient in obesity drug Wegovy and diabetes drug Ozempic and an amylin analogue. The amycretin pill combines the two modes of action in one molecule.
The company is also working on an injectable version of amycretin.
Reuters
LETTER: Doctors must stick to the label
WeightWatchers shares plunge as Oprah exits board
Indian pharma firms start making generic versions of weight-loss jabs
Weight-loss drugs fatten Eli Lilly and Novo Nordisk
Amgen opts for different route to weight-loss windfall
Novo CEO details strategy for Wegovy launches
Eli Lilly expects obesity and diabetes drugs to deliver hefty profit bump
Drugmakers target obesity market with deals and development
Novo Nordisk strikes research deals with US biotech firms
Adherence to Wegovy at 40% a year later, but still much higher than for older drugs
Novo Nordisk to boost production of drugs in France
Novo Nordisk invests $6bn in Wegovy production
EU pharma rules overhaul proposal may lead to decline in R&D share, group says
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
LETTER: Doctors must stick to the label
WeightWatchers shares plunge as Oprah exits board
Indian pharma firms start making generic versions of weight-loss jabs
Weight-loss drugs fatten Eli Lilly and Novo Nordisk
Amgen opts for different route to weight-loss windfall
Eli Lilly expects obesity and diabetes drugs to deliver hefty profit bump
Novo CEO details strategy for Wegovy launches
Drugmakers target obesity market with deals and development
Novo Nordisk strikes research deals with US biotech firms
Adherence to Wegovy at 40% a year later, but still much higher than for older ...
Novo Nordisk to boost production of drugs in France
Novo Nordisk invests $6bn in Wegovy production
EU pharma rules overhaul proposal may lead to decline in R&D share, group says
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.